E-mail this page Printer Friendly Version RSS E-mail Alerts View contacts Download Financial Tear Sheet 

2015 Press Releases

This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.

Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005
DateTitle 
04/23/15Quest Diagnostics Reports First Quarter 2015 Financial Results
-- Revenues of $1.84 billion, up 5.3% from 2014 -- Adjusted diluted EPS excluding amortization of $1.05, up 13% from 2014 -- Reported diluted EPS of $0.42 was negatively impacted by recent debt refinancing charges -- Guidance unchanged for full year revenue and adjusted diluted EPS excluding amortization MADISON, N.J., April 23, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that for ... 
Printer Friendly Version
04/21/15Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers
BRCA Share™ is a novel public-private initiative designed to enhance the clarity and quality of patient testing MADISON, N.J. and PARIS and BURLINGTON, N.C., April 21, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Inserm, the French National Institute of Health and Medical Research institution, today launched BRCA Share™, a novel datashare initiative they co-founded to provide scientists and laboratory organizations ... 
Printer Friendly Version
04/15/15FDA Clears the Simplexa™ Group A Strep Direct Test from Focus Diagnostics, a Quest Diagnostics Business
CYPRESS, Calif. and MADISON, N.J., April 15, 2015 /PRNewswire/ -- Focus Diagnostics, the clinical-laboratory products business of Quest Diagnostics (NYSE: DGX), today announced the FDA 510(k) clearance and CLIA moderate-complexity categorization for its Simplexa Group A Strep Direct Kit.  Simplexa Group A Strep Direct is a real-time polymerase chain reaction assay for the detection of Group A Streptococcus bacteria directly from throat swabs.  The most prevalent form of Group A Streptococcus... 
Printer Friendly Version
04/14/15HPV-Only Screening Misses More Cervical Cancers in Women 30 and Older Than Pap-Only or Pap-HPV Co-testing, Finds National Study
As many as 19% of women received false negatives for cervical cancer when HPV-only tested, finds Quest Diagnostics Health Trends™ study published in Cancer Cytopathology of 256,648 women, one of the largest of different screening tests for cervical cancer MADISON, N.J., April 14, 2015 /PRNewswire/ -- HPV-only screening is less likely to accurately detect cervical pre-cancer and cancer than testing that includes a Pap test in women 30-65 years of age, according to a new study published onlin... 
Printer Friendly Version
04/13/15Quest Diagnostics To Release First Quarter 2015 Financial Results On April 23
MADISON, N.J., April 13, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2015 results on Thursday, April 23, 2015, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The compan... 
Printer Friendly Version
04/09/15Quest Diagnostics to Launch Interactive Insights and IntelliTest Interactive Reports and Health Data Analytics Tools at HIMSS 2015
Company's HIT solutions turn health information into actionable insights to help ACOs, health systems, hospitals and physicians improve health care quality, outcomes and efficiencies MADISON, N.J., April 9, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, will unveil a suite of new technology solutions during the HIMSS 2015 Annual Conference & Exhibition, the industry's largest health IT educational program and exhibiti... 
Printer Friendly Version
04/02/15Quest Diagnostics Recognizes Five Strategic Partners with Supplier Excellence Awards
MADISON, N.J., April 2, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today awarded Supplier Excellence Awards to five companies at its 2015 Supplier Forum. Supplier Excellence awards recognize world class products, systems, or services that provide consistent and reliable performance; companies that develop and implement novel solutions to move the business forward; individuals who step up to the challenge and excel in ... 
Printer Friendly Version
03/31/15Quintiles and Quest Diagnostics to Form Joint Venture to Provide Global Clinical Trials Laboratory Services
Combines the complementary strengths and scale of leading biopharmaceutical services and diagnostic information services providers New entity creates superior value proposition through the depth and scale of its capabilities, services and expertise Business to help biopharmaceutical customers bring new drug therapies to market and support precision medicine Joint venture would have generated approximately $575 million in revenues in 2014 Quintiles will own 60% and Quest D... 
Printer Friendly Version
03/23/15Diabetes Diagnoses Surge in States that Expanded Medicaid Under the Affordable Care Act
Quest Diagnostics Health Trends™ study in Diabetes Care suggests health care reform has increased access to preventive health services, but only in states that expanded Medicaid MADISON, N.J., March 23, 2015 /PRNewswire/ -- People in states that expanded Medicaid under the Affordable Care Act (ACA) are far more likely to be newly identified with diabetes than in states that elected not to expand the public health care program, finds a new study by researchers at Quest Diagnostics (NYSE: DGX... 
Printer Friendly Version
03/19/15Quest Diagnostics Announces Early Tender Date Results of Cash Tender Offers for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 19, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the early tender results of its previously announced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $250 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 (the "2037 Notes") and 5.750% Senior Notes due 2040 (the "2040 Notes" and... 
Printer Friendly Version
03/18/15Quest Diagnostics Announces Pricing of Cash Tender Offers for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 18, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the determination of the pricing for its previously announced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $250 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 (the "2037 Notes") and 5.750% Senior Notes due 2040 (the "2040 N... 
Printer Friendly Version
03/10/15Quest Diagnostics to Enhance Diagnosis of Pediatric Neurological Disorders with Exclusive Whole Exome Sequencing from Personalis
Proprietary Neurome™ service provides insight into the genetic causes of neurological disorders so parents and health care providers can develop personalized care strategies MADISON, N.J., March 10, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of Neurome™, a whole exome sequencing service designed to aid the diagnosis of rare neurological disorders in pediatric populations. Personalis, I... 
Printer Friendly Version
03/05/15Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
MADISON, N.J., March 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it intends to offer $1,200,000,000 in aggregate principal amount of three series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions. The issuance of the notes will be subject to customary closing condi... 
Printer Friendly Version
03/05/15Quest Diagnostics Commences Cash Tender Offer for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has commenced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $250 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 and 5.750% Senior Notes due 2040 (collectively, the "Notes"). The terms and conditions of the Offers are ... 
Printer Friendly Version
03/05/15Quest Diagnostics Announces Amendments to the Prices Offered in its Previously Announced Cash Tender Offer for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it is amending the terms of its cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $250 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 (the "2037 Notes") and 5.750% Senior Notes due 2040 (the "2040 Notes" and, together with t... 
Printer Friendly Version
03/04/15Quest Diagnostics To Speak At The Barclays Global Healthcare Conference
MADISON, N.J., March 4, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Barclays Global Healthcare Conference in Miami.  Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Wednesday, March 11, 2015 at 1:05 p.m. Eastern Time. The presentation will be webcast l... 
Printer Friendly Version
02/20/15Quest Diagnostics Earns Fortune Magazine 2015 "World's Most Admired Companies" Designation
MADISON, N.J., Feb. 20, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been named a "Most Admired Company" by Fortune Magazine in the "Health Care: Pharmacy and Other Services" category. "We are proud that Quest Diagnostics is included on FORTUNE's 2015 World's Most Admired Companies list in our category," said Steve Rusckowski, President and CEO. "The honor is a true team accomplishment, and ... 
Printer Friendly Version
02/09/15Quest Diagnostics and Myriad Genetics End BRCA Patent Litigation
Agreement ensures continuing broad patient access to Quest's BRCAvantage™ services for evaluating genetic risk of developing breast, ovarian and other cancers MADISON, N.J., Feb. 9, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it and Myriad Genetics Inc. have reached an agreement that ends their BRCA gene-patent litigation.  Under the agreement, Quest Diagnostics and Myriad Genetics and its co-... 
Printer Friendly Version
01/29/15Quest Diagnostics Reports Fourth Quarter and Full Year 2014 Financial Results; Provides Guidance For Full Year 2015; Increases Dividend 15%
MADISON, N.J., Jan. 29, 2015 /PRNewswire/ -- Fourth quarter revenues from continuing operations of $1.9 billion, up 7.2% versus prior year Adjusted diluted EPS from continuing operations of $1.08, up 4.9% versus prior year Reported diluted EPS from continuing operations of $1.26, up 30% versus prior year Dividend increased 15% to $0.38 per quarter Full year 2015 revenues to grow 2% to 3% Full year 2015 adjusted diluted EPS excluding amortization expense expected to be between $4.... 
Printer Friendly Version
01/28/15Quest Diagnostics and CDC Expand Public Health Collaboration to Improve Hepatitis Diagnosis and Treatment
Multi-year fee-based contract for Quest's test data and analytics expertise aims to reveal insights from national testing trends to promote guideline-based care and better outcomes for 4.4 million Americans with viral hepatitis MADISON, N.J. and ATLANTA, Jan. 28, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it will collaborate with the Centers for Disease Control and Prevention (CDC) to identify tre... 
Printer Friendly Version
01/13/15Quest Diagnostics To Release Fourth Quarter And Full Year 2014 Financial Results On January 29
MADISON, N.J., Jan. 13, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2014 results on Thursday, January 29, 2015, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 321... 
Printer Friendly Version
01/08/15Quest Diagnostics Names New Health Plan Leader
MADISON, N.J., Jan. 8, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the appointment of veteran health plan executive Michael Cole as vice president of health plans for Quest Diagnostics.  "We are very focused on strengthening our relationships with health plan customers," said Steve Rusckowski, president and chief executive officer, Quest Diagnostics.  "Mike has the experience and leadership to build an... 
Printer Friendly Version
01/06/15Quest Diagnostics To Speak At The 33rd Annual J.P. Morgan Healthcare Conference
MADISON, N.J., Jan. 6, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco.  Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Wednesday, January 14, 2015 at 2:30 p.m. Eastern Time. The presentation will be... 
Printer Friendly Version
01/05/15Quest Diagnostics to Speak at the Goldman Sachs Healthcare CEOs Unscripted Conference
MADISON, N.J., Jan. 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Goldman Sachs Healthcare CEOs Unscripted Conference in Boston.  Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Tuesday, January 6, 2015 at 11:00 a.m. Eastern Time. The presentation will be we... 
Printer Friendly Version